Biological drug products present unique manufacturing and quality challenges due to their complexity, aseptic processing requirements, and critical public health impact.
In this episode of The GMP Insider, we explore how the FDA conducts inspections of biologics manufacturers through a systems-based, risk-management approach.
The FDA's biologics inspection program covers vaccines, blood derivatives, allergenic products, recombinant therapies, gene therapies, and cellular products. Manufacturers are expected to comply with both standard CGMP regulations and additional biologics-specific requirements under 21 CFR Parts 600–680.
Discussion topics include:
• Pre-license, pre-approval, and biennial inspections
• Level I versus Level II inspection coverage
• Systems-based inspection strategies
• Critical quality systems and risk management expectations
• Aseptic processing, lot release, and change control oversight
• The role of Team Biologics in inspection activities
FDA inspections are designed to ensure that biologics manufacturers maintain control over systems that impact product safety, purity, potency, and effectiveness. This risk-based inspection model allows FDA to focus resources on the highest-risk products and operations.